Search

everythinglearnresearchcommunity

for

Search:↓

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Cancer patients in sub-Saharan Africa face significant challenges during chemotherapy, highlighting the need for better patient care and support.

Alopecia areata patients have varied cancer risks, with some cancers being lower and others higher.

Some side effects of breast cancer chemotherapy, like neuropathy and nail loss, can last long after treatment.

Social support improves empowerment and quality of life for breast cancer patients with hair loss.

3D-bioprinting models of pancreatic cancer could help personalize treatments but need more testing.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

Male cancer patients have a higher risk of severe illness and death from COVID-19 than female patients.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Breast cancer patients should balance treatment with safe wellness practices to improve quality of life, consulting their oncologist first.

Breast cancer patients have lower hair zinc levels, which strongly decrease as BMI increases.

Some early breast cancer patients have long-term hair loss after chemotherapy, especially older and postmenopausal women.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Lung cancer patients on immunotherapy and chemotherapy often experience severe fatigue, drowsiness, and appetite loss.

Breast cancer patients undergoing chemotherapy often worry, lose weight, and cope by praying, meditating, or seeking support.

Dermatologists should carefully manage hair loss in cancer patients to improve their quality of life.

Horticultural therapy helped cancer patients feel hopeful and positive about their disease experience.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Patients with nonmelanoma skin cancers are most bothered by fear of progression, appearance concerns, and having cancer.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Early-onset colorectal cancer requires better physician awareness, risk-based screening, and stigma reduction to improve patient experiences.

Aumolertinib effectively controls lung cancer and improves quality of life.

Chemotherapy for breast cancer often causes significant and lasting hair loss.

Patients with hematologic cancer had mild anxiety, low surgical knowledge, and the pandemic increased their anxiety.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.

PCOS is linked to a higher risk of endometrial cancer but not ovarian or breast cancer, and more research is needed on its role in cancer development and treatment effects.